Answers are grounded in this paper and cite their sources.
We read with interest the paper by Jaiswal and colleagues,(1) but we would like to raise a series of concerns about it. The studied cohort (647 out of the original 6832 invited women) included individuals exposed to bone‐acting agents. Of the total of 151 women who sustained any fracture, 51 had received previous osteoporosis treatment and 33 were on current bisphosphonates; in sum, 84 (55.6% of the woman with incident fractures). The difference in bone material strength index (BMSi) levels in the current bisphosphonate users is reported as nonsignificant (the number of patients in the control group receiving current bisphosphonate treatment is not reported). The authors adjust the analyses by this factor but they do not report any adjustment by the use of previous medication, numerically more important and showing statistically significant differences in BMSi. Again, no numbers are provided in the control group for how many women have been on this “previous” treatment.
No takes yet. Share an insight, caveat, or question.
Díez‐Pérez et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: